PreviousNextExpandCollapseSearch

Web Page-Disease

Disease Phase Study No. Summary Status Total
Hide details for Advanced CancersAdvanced Cancers
  128
Hide details for Phase IPhase I
  79
NCI9591   A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer
Patients with Hepatic Dysfunction
  Open  
2015-0838   Evaluation of an Alternative Schedule for CRLX101 Alone and in Combination with Bevacizumab in Subjects with Advanced Solid Tumor Malignancies  Open  
2015-0627   An open-label, non-randomized, multicenter Phase I study to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose of oral MKNK1 inhibitor BAY 1143269 given alone or in combination with intravenous docetaxel in subjects with advanced solid tumors  Open  
2015-0621   A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, and Pharmacokinetics in Patients with Advanced Malignancies  Open  
2015-0480   A Phase 1 Open-Label, Multicenter, Dose-Escalation Study of PRN1371, a FGFR1-4 Kinase Inhibitor, in Adult Patients with Advanced Solid Tumors, followed by an Expansion Cohort in Patients with FGFR1, 2, 3, or 4 Genetic Alterations  Open  
2015-0468   A PHASE 1A/B STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF ETC-1922159 IN ADVANCED SOLID TUMOURS  Open  
2015-0465   A Phase I Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 in Patients with Advanced Solid Tumors or Lymphomas Expressing Wild-Type p53 Protein  Open  
2015-0384   An Open-Label Multicenter Phase 1 Study of E7046 in Subjects With Selected Advanced Malignancies  Open  
2015-0310   A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-881 in Patients with Advanced Solid Tumors, Including Gliomas, with an IDH1 and/or IDH2 Mutation  Open  
2015-0282   A Phase 1/2, Multicenter, Open-Label, Dose-Escalation Study of AG-221 in Subjects with Advanced Solid Tumors, including Glioma, and with Angioimmunoblastic T-cell Lymphoma, that Harbor an IDH2 Mutation  Open  
2015-0261   A First-in-Human Study of Repeat Dosing with REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death-1(PD-1), as Single Therapy and in Combination with Other Anti-Cancer Therapies in Patients with Advanced Malignancies  Open  
2015-0220   Phase 1 Dose-escalation Study of Radio-labeled Immunotherapeutic, FF-21101(90Y), for the Treatment of Advanced Cancer  Open  
2015-0158   A Phase 1/2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors  Open  
2015-0054   Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies  Open  
2015-0033   Phase I Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered CUDC-907, an HDAC and PI3K Inhibitor, in Subjects with Advanced/Relapsed Solid Tumors  Open  
2015-0028   An Open-Label, Dose-escalation/expansion Phase 1 Study of ASP4132 Given Orally to Subjects with Advanced Refractory Solid Tumors and Lymphoma  Open  
2014-1099   A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies  Open  
2014-1056   Phase 1 Study of the Oral TRK Inhibitor LOXO-101 in Adult Patients with Solid Tumors  Open  
2014-1054   A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of SM04755 in Subjects with Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer  Open  
2014-1052   A Phase 1 Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination with Tremelimumab (Anti-CTLA-4 Antibody) in Subjects with Advanced Solid Tumors  Open  
2014-1045   A phase I, gene alteration-based, open label, multicenter study of oral Debio 1347 (CH5183284) in patients with advanced solid malignancies, whose tumours have an alteration of the FGFR 1, 2 or 3 genes  Open  
2014-1022   An Open-Label, Phase I, Dose-Escalation Trial to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Pharmacodynamics of the Anti-FGFR2 Antibody Drug Conjugate BAY 1187982 in Subjects with Advanced Solid Tumors Known to Express FGFR2  Open  
2014-1006   A Phase I Study of IDH305 in Patients with Advanced Malignancies that Harbor IDH1R132 Mutations  Open  
2014-1005   A Phase 1/1b Study of MGCD516 in Patients with Advanced Solid Tumor Malignancies  Open  
2014-0999   A Phase I, multicenter, open-label dose escalation and expansion study of PCA062, administered intravenously in adult patients with pCAD-positive tumors  Open  
2014-0959   A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects with Advanced Cancer  Open  
2014-0952   A Phase 1b Study Evaluating the Safety, Tolerability and Immunogenicity of CMB305 (Sequentially Administered LV305 and G305) in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1  Open  
2014-0891   A Phase 1 study of KBP-5209 in patients with advanced solid tumors  Open  
PreviousNextExpandCollapseSearch